Concentration of Contezolid in Cerebrospinal Fluid and Serum in a Patient with Tuberculous Meningoencephalitis: A Case Report

Wanru Guo,Ming Hu,Nana Xu,Yanwan Shangguan,Jiafeng Xia,Wenjuan Hu,Xiaomeng Li,Qingwei Zhao,Kaijin Xu
DOI: https://doi.org/10.1016/j.ijantimicag.2023.106875
IF: 15.441
2023-01-01
International Journal of Antimicrobial Agents
Abstract:Central nervous system (CNS) tuberculosis (TB) is a devastating and often life-threatening disease caused by Mycobacterium tuberculosis. Contezolid, a new oxazolidinone, has demonstrated potent antimycobacterial activity in both in-vivo and in-vitro studies, with lower toxicity than linezolid. However, pharmacokinetic data are still not available for contezolid in the CNS of patients with CNS TB. This article reports the steady-state concentrations of contezolid in serum and cerebrospinal fluid (CSF) of a patient receiving contezolid as part of multi-drug treatment for tuberculous meningoencephalitis. At weeks 7 and 11 (7 h post-dose) after initiation of contezolid therapy, the serum concentrations of contezolid were 9.64 mg/L and 9.36 mg/L, respectively. In CSF, the observed concentrations of contezolid were 0.54 mg/L and 1.15 mg/L, respectively. The CSF:serum concentration ratios were 0.056 and 0.123 at weeks 7 and 11, respectively. The observed concentrations in CSF were above the minimum inhibitory concentration of contezolid against M. tuberculosis, and were close to the estimated serum unbound fraction of contezolid (10%), suggesting that unbound contezolid has high CSF permeability.
What problem does this paper attempt to address?